Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778673 | 0.91 | KDM4E (0.42) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL2534941 | 0.85 | KDM4E (0.62) | KDM4ECYP3A4CYP2C19HIF1AACHE | |
| SCHEMBL3420261 | 0.81 | POLB (0.52) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL8936155 | 0.81 | POLB (0.72) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL30827901 | 0.81 | ACHE (0.42) | KDM4EKMT2AMEN1ACHEMPO | |
| SCHEMBL23202854 | 0.81 | ACHE (0.42) | KDM4EKMT2AMEN1ACHEMPO | |
| SCHEMBL14960133 | 0.81 | POLB (0.61) | KDM4ECYP3A4CYP2C19POLBKMT2A | |
| SCHEMBL1600117 | 0.78 | KDM4E (0.49) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL3060777 | 0.78 | KDM4E (0.49) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL5434270 | 0.78 | KDM4E (0.50) | KDM4ECYP3A4CYP2C19HIF1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9139538-B2 | Quinolinyl glucagon receptor modulators | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2734503-B1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150099882-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8927577-B2 | Quinolinyl glucagon receptor modulators | PFIZER INC. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2734503-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | Pfizer Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140135338-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2013014569-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-20070185079-A1 | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1706384-A1 | THERAPEUTIC AGENTS I | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005066132-A1 | THERAPEUTIC AGENTS I | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099882-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | KDM4E 4299/4885CYP3A4 1275/4885CYP2C19 1396/4885 |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | KDM4E 4299/4885CYP3A4 1275/4885CYP2C19 1396/4885 |
| US-20140135338-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | KDM4E 4299/4885CYP3A4 1275/4885CYP2C19 1396/4885 |
| US-20070185079-A1 | Therapeutic agents I | HTT, GRIN2A, GRIN1 | KDM4E 2659/4885CYP3A4 2988/4885CYP2C19 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.